Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DCTH
stocks logo

DCTH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
22.80M
+103.57%
-0.055
-50%
19.99M
+32.37%
0.048
+58.33%
25.28M
+27.75%
0.055
-21.43%
Estimates Revision
The market is revising Downward the revenue expectations for Delcath Systems, Inc. (DCTH) for FY2025, with the revenue forecasts being adjusted by -10.63% over the past three months. During the same period, the stock price has changed by -13.99%.
Revenue Estimates for FY2025
Revise Downward
down Image
-10.63%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-13.99%
In Past 3 Month
Wall Street analysts forecast DCTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DCTH is 25.50 USD with a low forecast of 21.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast DCTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DCTH is 25.50 USD with a low forecast of 21.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.020
sliders
Low
21.00
Averages
25.50
High
30.00
Current: 10.020
sliders
Low
21.00
Averages
25.50
High
30.00
Craig-Hallum
Chase Knickerbocker
Buy
downgrade
$24 -> $20
2025-10-21
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$24 -> $20
2025-10-21
downgrade
Buy
Reason
Craig-Hallum analyst Chase Knickerbocker lowered the firm's price target on Delcath Systems to $20 from $24 and keeps a Buy rating on the shares following the company's prerelease/guidance and CHOPIN data at ESMO. Phase 2 CHOPIN study data presented at ESMO showed a clear benefit for Chemosat/Hepzato combined with checkpoint inhibitors in metastatic uveal melanoma. However, this news was overshadowed by disappointing Q3 and FY25 guidance, with Q3 revenue guided to $20.5M and FY25 revenue to $83M-$85M, the firm says. Craig-Hallum expects the CHOPIN data to inform U.S. use of Hepzato in sequence with checkpoint inhibitors, potentially driving increased volume in the second half of 2026.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$31 -> $30
2025-10-20
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$31 -> $30
2025-10-20
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Delcath Systems to $30 from $31 and keeps a Buy rating on the shares after the company issued preliminary Q3 financial results and lowered revenue guidance for FY2025. Additionally, Delcath presented a clinical data update from the investigator-initiated CHOPIN randomized Phase 2 trial at the 2025 annual Congress of European Society for Medical Oncology, notably that the clinical study met its primary endpoint of improved one-year progression-free survival.
Clear Street
Buy
maintain
$27 -> $28
2025-10-20
Reason
Clear Street
Price Target
$27 -> $28
2025-10-20
maintain
Buy
Reason
Clear Street raised the firm's price target on Delcath Systems to $28 from $27 and keeps a Buy rating on the shares. The stock is trading lower on the company's "soft" preliminary Q3 results and 2025 revenue guidance, the analyst tells investors in a research note. However, the firm attributes the results to pricing dynamics and new patient starts, which it feels are "likely a blip." The CHOPIN trial results will lead to increased penetration of Hpezato into the metastatic uveal melanoma population, contends Clear Street. The firm sees today's selloff as a buying opportunity. The stock is down 5% to $11.38 in midday trading.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$29 -> $31
2025-08-07
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$29 -> $31
2025-08-07
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Delcath Systems to $31 from $29 and keeps a Buy rating on the shares following the Q2 report. The firm says robust Hepzato adoption continues to drive growth.
H.C. Wainwright
Buy
maintain
$24 -> $29
2025-05-23
Reason
H.C. Wainwright
Price Target
$24 -> $29
2025-05-23
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Delcath Systems to $29 from $24 and keeps a Buy rating on the shares after the company announced its intention to enter into a Medicaid National Drug Rebate agreement. This strategic move is prudent given that it could not only aid in accessing a larger patient base but also help in achieving sustainable growth, the analyst tells investors in a research note.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Maintains
$22 → $24
2025-03-07
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$22 → $24
2025-03-07
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Delcath Systems Inc (DCTH.O) is 66.62, compared to its 5-year average forward P/E of -3.98. For a more detailed relative valuation and DCF analysis to assess Delcath Systems Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.98
Current PE
66.62
Overvalued PE
57.56
Undervalued PE
-65.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.94
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
22.61
Undervalued EV/EBITDA
-34.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
15.35
Current PS
0.00
Overvalued PS
31.28
Undervalued PS
-0.58
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

DCTH News & Events

Events Timeline

(ET)
2025-12-03
16:10:00
Delcath Systems Publishes Study on Liver-Dominant Metastatic Uveal Melanoma Outcomes
select
2025-11-20 (ET)
2025-11-20
16:02:25
Delcath Systems approves $25 million stock repurchase initiative
select
2025-11-18 (ET)
2025-11-18
09:31:43
Delcath Systems releases evaluation of Hepzato Kit
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-04Newsfilter
Delcath Publishes 10-Year Study on Liver Cancer Treatment with 29.1 Months Survival Rate
  • Survival Rate Improvement: Delcath's published study reveals that 38 patients with liver-dominant metastatic uveal melanoma, who underwent 99 CHEMOSAT® procedures, achieved a median overall survival of 29.1 months, significantly surpassing previous reports and underscoring the therapy's efficacy and safety.
  • Impact of Treatment Cycles: The study indicates that patients receiving ≥3 PHP treatments had a median survival of 29.8 months compared to 21.4 months for those with ≤2 cycles, demonstrating the positive impact of repeated treatment cycles on survival and a ~40% reduction in death risk.
  • No Treatment-Related Deaths: The study reported no treatment-related deaths and only 10.5% of patients experienced serious adverse events, highlighting the safety of CHEMOSAT® in real-world applications and enhancing confidence in its clinical use.
  • Clinical Evidence Support: This research provides critical clinical evidence for treating liver-dominant metastatic uveal melanoma, emphasizing the importance of high-volume medical centers in optimizing treatment outcomes, which may drive the adoption of new management strategies.
[object Object]
Preview
8.0
11-24NASDAQ.COM
Are Options Traders Aware of Insights About Delcath Systems Stock That We Are Not?

  • Implied Volatility in Options Market: Delcath Systems, Inc. (DCTH) has seen significant implied volatility in its January 2025 $2.50 Call options, indicating that investors expect a major price movement, potentially due to an upcoming event.

  • Analyst Sentiment: Currently, Delcath holds a Zacks Rank of #3 (Hold) in the Medical - Instruments Industry, with no analysts increasing their earnings estimates recently, leading to a consensus estimate of a loss of six cents per share for the current quarter.

  • Options Trading Strategy: The high implied volatility may attract options traders looking to sell premium, as they anticipate that the stock may not move as much as expected by expiration, which is a common strategy to capture decay.

  • Investment Opportunities: Zacks Investment Research highlights several stocks with high growth potential, suggesting that investors may find opportunities in lesser-known stocks that could yield significant returns in the coming months.

[object Object]
Preview
8.0
11-21NASDAQ.COM
Biotech Stocks Fluctuate Post-Market: Delcath Gains from Buyback, BioVie and Cassava Recover

  • Delcath Systems' Buyback Announcement: Delcath Systems saw a 4.02% increase in after-hours trading to $8.52 following the announcement of a $25 million share repurchase program, indicating confidence in its long-term outlook.

  • BioVie Inc. Gains Despite No News: BioVie Inc. rose 13.39% to $1.44 in extended trading, rebounding from a decline during the regular session, with the increase attributed to speculative trading rather than new company-specific news.

  • Cassava Sciences' After-Hours Rally: Cassava Sciences advanced 9.17% to $2.87 after hours, recovering from a regular session drop, as investors reacted to its recent Q3 results showing a reduced net loss and significant cash reserves.

  • Enlivex Therapeutics' Modest Increase: Enlivex Therapeutics experienced a 4.24% rise to $0.95 in after-hours trading, despite no new developments reported on Thursday.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Delcath Systems Inc (DCTH) stock price today?

The current price of DCTH is 10.02 USD — it has increased 3.73 % in the last trading day.

arrow icon

What is Delcath Systems Inc (DCTH)'s business?

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

arrow icon

What is the price predicton of DCTH Stock?

Wall Street analysts forecast DCTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DCTH is 25.50 USD with a low forecast of 21.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Delcath Systems Inc (DCTH)'s revenue for the last quarter?

Delcath Systems Inc revenue for the last quarter amounts to 20.56M USD, increased 83.60 % YoY.

arrow icon

What is Delcath Systems Inc (DCTH)'s earnings per share (EPS) for the last quarter?

Delcath Systems Inc. EPS for the last quarter amounts to 0.02 USD, decreased -66.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for Delcath Systems Inc (DCTH)'s fundamentals?

The market is revising Downward the revenue expectations for Delcath Systems, Inc. (DCTH) for FY2025, with the revenue forecasts being adjusted by -10.63% over the past three months. During the same period, the stock price has changed by -13.99%.
arrow icon

How many employees does Delcath Systems Inc (DCTH). have?

Delcath Systems Inc (DCTH) has 96 emplpoyees as of December 05 2025.

arrow icon

What is Delcath Systems Inc (DCTH) market cap?

Today DCTH has the market capitalization of 340.78M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free